Diego Rodrigues falci
Médico infectologista
CRM 25224-RS
Sobre
O Dr. Diego Rodrigues Falci é formado em Medicina pela Universidade Federal do Rio Grande do Sul (UFRGS) em 2000, com residência médica em Infectologia na Santa Casa de Porto Alegre (2003). Tem também Mestrado em Medicina: Ciências Médicas pela UFRGS (2009) e Doutorado em Patologia pela Universidade Federal de Ciências da Saúde de Porto Alegre (2015).
Atua como Professor de Infectologia na Escola de Medicina da Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), e como Médico Infectologista no Hospital São Lucas da PUCRS, Hospital de Clínicas de Porto Alegre e Hospital Moinhos de Vento.
O Dr. Falci é pesquisador prolífico na área de doenças infecciosas, tendo publicado mais de 50 artigos científicos indexados na base PubMed/MEDLINE. É Professor do Programa de Pós-Graduação em Medicina: Ciências Médicas da UFRGS, conduzindo estudos acadêmicos, em especial na área de Micologia Médica e infecções em pacientes imunossuprimidos. Também tem experiência como Investigador Principal de estudos clínicos na área de doenças infecciosas.
Marque uma consulta
PRODUÇÃO científica
ARTIGOS CIENTÍFICOS NA BASE PUBMED
1. High rate of Clostridioides difficile colonization in patients admitted to intensive care: A prospective cohort study.
Spagnól MF, Signori D, Comerlato PH, Tonietto TA, Caierão J, Pasqualotto AC, Martins AF, Falci DR. Anaerobe. 2022 Feb 21:102538.
2. The Current State of Clinical Mycology in Eastern and South-Eastern Europe.
Driemeyer C, Falci DR, Hoenigl M, Cornely OA, Chakrabarti A, Gangneux JP, Segal E, Jürna-Ellam M, Matos T, Meis JF, Perfect JR, Arsenijevic VA, Mares M, Serban DE, Pasqualotto AC.
Med Mycol. 2022 Feb 23:myac017.
3. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C, Peppercorn A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE; COMET-ICE Investigators.
N Engl J Med. 2021 Nov 18;385(21):1941-1950.
4. Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): A randomized clinical trial.
Boniatti MM, Pellegrini JAS, Marques LS, John JF, Marin LG, Maito LRDM, Lisboa TC, Damiani LP, Falci DR.
PLoS One. 2020 Sep 21;15(9):e0239452.
5. Candidaemia Mortality Has not Changed Over the Last 2 Decades in Brazil.
Dalla Lana DF, Falci DR, Sanha V, Jaskulski Filho SD, Schuch F, Pasqualotto AC.
Mycopathologia. 2020 Aug;185(4):685-690.
6. Clinical Characteristics of Covid-19 in China.
Zavascki AP, Falci DR.
N Engl J Med. 2020 May 7;382(19):1859.
7. Cranial syphilitic gumma.
Pasqualotto AC, Othman HAN, Dias AB, Grando RM, Ulysséa LMT, Jaskulski Filho SD, Hallal RC, Falci DR.
Int J Infect Dis. 2020 Jun;95:160-161.
8. Genetic relatedness, Virulence factors and Antimicrobial Resistance of C. difficile strains from hospitalized patients in a multicentric study in Brazil.
Saldanha GZ, Pires RN, Rauber AP, de Lima-Morales D, Falci DR, Caierão J, Pasqualotto AC, Martins AF.
J Glob Antimicrob Resist. 2020 Sep;22:117-121.
9. Clinical Use of Polymyxin B.
Rigatto MH, Falci DR, Zavascki AP.
Adv Exp Med Biol. 2019;1145:197-218.
10. Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection.
Falci DR, Monteiro AA, Braz Caurio CF, Magalhães TCO, Xavier MO, Basso RP, Melo M, Schwarzbold AV, Ferreira PRA, Vidal JE, Marochi JP, Godoy CSM, Soares RBA, Paste A, Bay MB, Pereira-Chiccola VL, Damasceno LS, Leitão TDMJS, Pasqualotto AC.
Open Forum Infect Dis. 2019 Apr 13;6(4):ofz073.
11. Polymyxin Acute Kidney Injury: Dosing and Other Strategies to Reduce Toxicity.
Nation RL, Rigatto MHP, Falci DR, Zavascki AP.
Antibiotics (Basel). 2019 Mar 14;8(1):24.
12. High frequency of Clostridium difficile infections in Brazil: Results from a multicenter point-prevalence study.
Pires RN, Falci DR, Monteiro AA, Caurio CFB, Tuon FF, Medeiros EA, França IL, John JF, Sukiennik TCT, Saldanha GZ, Martins AF, Pasqualotto AC.
Infect Control Hosp Epidemiol. 2019 Apr;40(4):484-485.
13. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Medeiros GS, Rigatto MH, Falci DR, Zavascki AP.
Int J Antimicrob Agents. 2019 Feb;53(2):152-157.
14. Clinical mycology in Latin America and the Caribbean: A snapshot of diagnostic and therapeutic capabilities.
Falci DR, Pasqualotto AC.
Mycoses. 2019 Apr;62(4):368-373. doi: 10.1111/myc.12890.
15. Impact of extended-spectrum β-lactamases and carbapenem-resistant Gram-negative infections on sepsis mortality at the emergency department: a cohort study.
Sabino S, Monroy H, Jara C, Lopez O, Ramos F, Falci DR, Rigatto MH.
J Hosp Infect. 2019 Feb;101(2):190-191.
16. Impact of polymyxin-B-associated acute kidney injury in 1-year mortality and renal function recovery.
Gomes EC, Falci DR, Bergo P, Zavascki AP, Rigatto MH.
Int J Antimicrob Agents. 2018 Jul;52(1):86-89.
17. Hypervirulent Clostridium difficile Strain Has Arrived in Brazil.
Pires RN, Monteiro AA, Saldanha GZ, Falci DR, Caurio CFB, Sukiennik TCT, Adam FC, Pasqualotto AC, Martins AF.
Infect Control Hosp Epidemiol. 2018 Mar;39(3):371-373.
18. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
John JF, Falci DR, Rigatto MH, Oliveira RD, Kremer TG, Zavascki AP.
Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01617-17.
19. Malaria in Southern Brazil: a potential threat for a non-endemic region.
Moreira DL, Cardoso JC, Deboni SC, Falci DR.
Braz J Infect Dis. 2017 Nov-Dec;21(6):678-679.
20. Neglected endemic mycoses.
Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T, Pasqualotto AC.
Lancet Infect Dis. 2017 Nov;17(11):e367-e377.
21. A Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives.
Falci DR, Stadnik CMB, Pasqualotto AC.
Infect Dis Ther. 2017 Jun;6(2):213-223.
22. Absence of Correlation Between Vancomycin Consumption and Minimum Inhibitory Concentration of Methicillin-Resistant Staphylococcus aureus Isolates.
Riche CVW, da Silva RCF, Ferreira JAS, Dias CAG, Falci DR.
Infect Control Hosp Epidemiol. 2017 Jun;38(6):751-753.
23. Progressive disseminated histoplasmosis: a systematic review on the performance of non-culture-based diagnostic tests.
Falci DR, Hoffmann ER, Paskulin DD, Pasqualotto AC.
Braz J Infect Dis. 2017 Jan-Feb;21(1):7-11.
24. Characteristics of serogroup 20 S.pneumoniae isolates from Brazil.
Caierão J, Sant'Anna FH, Hawkins P, Cunha GR, Mott M, Falci DR, d'Azevedo PA, McGee L, Dias C.
BMC Infect Dis. 2016 Aug 15;16(1):418.
25. Disseminated histoplasmosis and AIDS: a prospective and multicentre study to evaluate the performance of different diagnostic tests.
Hoffmann ER, Daboit TC, Paskulin DD, Monteiro AA, Falci DR, Linhares T, Flores JM, Goldani LZ, de Melo MG, Behar PR, Pasqualotto AC.
Mycoses. 2017 Jan;60(1):20-24.
26. Has Aspergillus PCR Come to the Age of Maturity?
Pasqualotto AC, Falci DR.
Mycopathologia. 2016 Oct;181(9-10):623-4. doi: 10.1007/s11046-016-0033-4. Epub 2016 Jun 29.
27. Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.
Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, Zavascki AP.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2443-9.
28. Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B.
Rigatto MH, Falci DR, Lopes NT, Zavascki AP.
Int J Antimicrob Agents. 2016 Feb;47(2):146-50.
29. The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil.
Lopes CA, Soares MA, Falci DR, Sprinz E.
Biomed Res Int. 2015;2015:738528.
30. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.
Zavascki AP, Manfro RC, Maciel RA, Falci DR.
Ann Pharmacother. 2015 Oct;49(10):1171-2.
31. Lactobacillus rhamnosus bacteremia in a kidney transplant recipient.
Falci DR, Rigatto MH, Cantarelli VV, Zavascki AP.
Transpl Infect Dis. 2015 Aug;17(4):610-2.
32. Hematological toxicities associated with amphotericin B formulations.
Falci DR, da Rosa FB, Pasqualotto AC.
Leuk Lymphoma. 2015;56(10):2889-94.
33. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, Costa LW, Zavascki AP.
J Antimicrob Chemother. 2015 May;70(5):1552-7.
34. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR, da Rosa FB, Pasqualotto AC.
Mycoses. 2015 Feb;58(2):104-12.
35. Burden of isolation for multidrug-resistant organisms in a tertiary public hospital in Southern Brazil.
Pereira PR, Isaakidis P, Hinderaker SG, Ali E, van den Boogaard W, Viana KS, Cassol R, Falci DR.
Am J Infect Control. 2015 Feb;43(2):188-90.
36. Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil.
Rozales FP, Ribeiro VB, Magagnin CM, Pagano M, Lutz L, Falci DR, Machado A, Barth AL, Zavascki AP.
Int J Infect Dis. 2014 Aug;25:79-81.
37. Heteroresistance to carbapenems in New Delhi metallo-β-lactamase-1-producing isolates: a challenge for detection?
Zavascki AP, Falci DR, da Silva RC, Dalarosa MG, Ribeiro VB, Rozales FP, Luz DI, Magagnin CM, Vieira FJ, Sampaio JM, Barth AL.
Infect Control Hosp Epidemiol. 2014 Jun;35(6):751-2.
38. Detection of OXA-370, an OXA-48-related class D β-lactamase, in Enterobacter hormaechei from Brazil.
Sampaio JL, Ribeiro VB, Campos JC, Rozales FP, Magagnin CM, Falci DR, da Silva RC, Dalarosa MG, Luz DI, Vieira FJ, Antochevis LC, Barth AL, Zavascki AP.
Antimicrob Agents Chemother. 2014 Jun;58(6):3566-7.
39. Carbapenem-resistant GES-5-producing Klebsiella pneumoniae in Southern Brazil.
Ribeiro VB, Falci DR, Rozales FP, Barth AL, Zavascki AP.
Braz J Infect Dis. 2014 Mar-Apr;18(2):231-2.
40. Detection of NDM-1-, CTX-M-15-, and qnrB4-producing Enterobacter hormaechei isolates in Brazil.
Carvalho-Assef AP, Pereira PS, Albano RM, Berião GC, Tavares CP, Chagas TP, Marques EA, Timm LN, Da Silva RC, Falci DR, Asensi MD.
Antimicrob Agents Chemother. 2014;58(4):2475-6.
41. Detection of bla(GES-5) in carbapenem-resistant Kluyvera intermedia isolates recovered from the hospital environment.
Ribeiro VB, Zavascki AP, Rozales FP, Pagano M, Magagnin CM, Nodari CS, da Silva RC, Dalarosa MG, Falci DR, Barth AL.
Antimicrob Agents Chemother. 2014;58(1):622-3.
42. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.
Falci DR, Pasqualotto AC.
Infect Drug Resist. 2013 Oct 22;6:163-74.
43. Geotrichum capitatum fungaemia: an unusual pathogen in critically-ill-related infections.
Nedel WL, Moraes VD, Falci DR, Pasqualotto AC.
Anaesth Intensive Care. 2013 Sep;41(5):685-7.
44. Isolation of NDM-producing Providencia rettgeri in Brazil.
Carvalho-Assef AP, Pereira PS, Albano RM, Berião GC, Chagas TP, Timm LN, Da Silva RC, Falci DR, Asensi MD.
J Antimicrob Chemother. 2013 Dec;68(12):2956-7.
45. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP.
Clin Infect Dis. 2013 Aug;57(4):524-31.
46. Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis.
Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki AP, Li J.
J Antimicrob Chemother. 2013 Mar;68(3):674-7.
47. Polymyxin B consumption and incidence of gram-negative bacteria intrinsically resistant to polymyxins.
Falci DR, Pacheco LS, Puga LS, da Silva RC, Alves AP, Behar PR, Zavascki AP.
Infect Control Hosp Epidemiol. 2012 May;33(5):536-7.
48. Chronic slowly progressive monoarthritis tuberculosis of the hip without systemic symptoms mimicking osteoarthritis: a case report.
Ramos CG, Alves MD, Pires dos Santos R, Falci D, Goldani LZ.
Cases J. 2009 Mar 10;2:6457.
49. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity.
Falci DR, Lunardi LW, Ramos CG, Bay MB, Aquino VR, Goldani LZ.
Clin Infect Dis. 2010 Mar 1;50(5):e26-9.
50. Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.
Falci DR, dos Santos RP, Wirth F, Goldani LZ.
Mycoses. 2011 Mar;54(2):91-8.
